Chylothorax

Chylothorax is a pathological condition characterized by the accumulation of chyle, a milky, lipid-rich lymphatic fluid, within the pleural space. This fluid originates from the thoracic duct or its major tributaries, which drain the gastrointestinal tract and lower body. The condition is defined by the presence of a modified transudate or exudate with a high triglyceride content (typically >100 mg/dL) and a cholesterol-to-triglyceride ratio of less than 1. Chylothorax can be classified as traumatic (due to blunt or penetrating injury to the thoracic duct) or non-traumatic (idiopathic, neoplastic, or due to other underlying diseases). In veterinary medicine, it is most commonly seen in dogs and cats, with a predilection for certain breeds. The accumulation of chyle in the pleural space leads to respiratory compromise due to lung compression, and if chronic, can result in fibrosing pleuritis, a severe complication that impairs lung expansion and carries a poor prognosis. Surgical management is often indicated when medical therapy fails, with thoracic duct ligation and cisterna chyli ablation being the most common procedures.

The etiology of chylothorax can be broadly divided into traumatic and non-traumatic causes. Traumatic chylothorax results from direct injury to the thoracic duct, which can occur due to blunt trauma (e.g., vehicular accidents, falls) or penetrating wounds (e.g., bite wounds, gunshots). The thoracic duct is particularly vulnerable to injury at the level of the caudal thoracic vertebrae, where it crosses from the right to the left side of the thorax. Iatrogenic trauma during thoracic surgery, such as esophageal surgery or lung lobectomy, can also lead to chylothorax. Non-traumatic causes include idiopathic chylothorax, which is the most common form in dogs and cats, and is often associated with right-sided heart failure, cranial vena cava thrombosis, or pericardial disease. Neoplastic conditions, such as lymphoma, thymoma, or metastatic disease, can obstruct or invade the thoracic duct or its tributaries, leading to chylous effusion. Other causes include fungal infections (e.g., histoplasmosis), heartworm disease, and congenital abnormalities of the lymphatic system. In cats, chylothorax is frequently associated with cardiomyopathy, particularly hypertrophic cardiomyopathy, which increases venous pressures and lymphatic flow.

Chylothorax is an uncommon condition in small animal practice but is seen with relative frequency in certain breeds. In dogs, Afghan Hounds, Shiba Inus, and Chow Chows are overrepresented, suggesting a possible genetic predisposition to lymphatic abnormalities. The condition can occur at any age, but a bimodal distribution is observed, with a peak in young animals (often traumatic) and another in middle-aged to older animals (often idiopathic or neoplastic). There is no significant sex predilection. In cats, the condition is more common in purebred cats, particularly Siamese and Himalayan breeds, and is often associated with underlying cardiac disease. The overall incidence is estimated to be less than 1% of all thoracic effusions in dogs and cats, but it represents a significant diagnostic and therapeutic challenge. The prognosis is guarded, especially in chronic cases where fibrosing pleuritis has developed.

The pathophysiology of chylothorax involves the leakage of chyle from the thoracic duct or its major branches into the pleural space. The thoracic duct is the primary lymphatic vessel that drains chyle from the gastrointestinal tract and lower body into the venous system at the junction of the left jugular and subclavian veins. The duct typically courses through the aortic hiatus of the diaphragm, ascends in the caudal mediastinum, and crosses from the right to the left side of the thorax at the level of the 5th to 7th thoracic vertebrae. Any disruption of the duct, whether due to trauma, increased intraluminal pressure, or obstruction, can result in chyle leakage. The chyle itself is composed of triglycerides, chylomicrons, lymphocytes, and fat-soluble vitamins, and its accumulation in the pleural space triggers an inflammatory response. Over time, the presence of chyle stimulates the proliferation of fibroblasts and the deposition of fibrin, leading to fibrosing pleuritis. This condition is characterized by the formation of a thick, fibrous peel over the visceral and parietal pleura, which restricts lung expansion and results in chronic respiratory distress. The loss of lymphocytes and immunoglobulins in the chyle can also lead to immunosuppression, increasing the risk of secondary infections.

Predisposing factors for chylothorax include breed predisposition, as noted in Afghan Hounds, Shiba Inus, and Chow Chows, which may have congenital lymphatic abnormalities. Underlying cardiac disease, particularly right-sided heart failure and pericardial disease, increases venous pressures and lymphatic flow, predisposing to chyle leakage. Cranial vena cava thrombosis, often associated with indwelling catheters or hypercoagulable states, can also lead to chylothorax. Neoplastic diseases, such as lymphoma and thymoma, can obstruct lymphatic drainage. Trauma, including vehicular accidents and bite wounds, is a significant risk factor, especially in young, active animals. Iatrogenic injury during thoracic surgery is a potential risk, particularly during procedures involving the caudal mediastinum. In cats, hypertrophic cardiomyopathy is a major predisposing factor. Other factors include heartworm disease, fungal infections, and congenital abnormalities of the thoracic duct.

The clinical signs of chylothorax are primarily related to respiratory compromise and the underlying cause. Common signs include tachypnea, dyspnea, exercise intolerance, and coughing. In severe cases, open-mouth breathing and cyanosis may be observed. Physical examination may reveal muffled heart and lung sounds on thoracic auscultation, particularly in the ventral lung fields, due to the presence of pleural fluid. Percussion of the chest may elicit a dull sound over the fluid line. In chronic cases, weight loss, lethargy, and anorexia are common. If the underlying cause is neoplastic or cardiac, additional signs such as peripheral lymphadenopathy, ascites, or cardiac murmurs may be present. In traumatic cases, signs of thoracic trauma, such as rib fractures or pulmonary contusions, may be evident. The onset of clinical signs can be acute or insidious, depending on the rate of fluid accumulation.

Differential diagnoses for chylothorax include other causes of pleural effusion, such as: 1) Pyothorax: Purulent exudate due to bacterial infection, often associated with fever, toxic neutrophils on cytology, and positive bacterial culture. 2) Feline infectious peritonitis (FIP): A protein-rich effusion with high globulin levels, positive Rivalta test, and characteristic histopathology. 3) Heart failure: Transudate or modified transudate due to increased hydrostatic pressure, with cardiomegaly on radiographs and response to diuretics. 4) Neoplasia: Hemorrhagic or modified transudate due to thoracic masses, with neoplastic cells on cytology or biopsy. 5) Lung lobe torsion: Hemorrhagic effusion with radiographic signs of lobar consolidation and torsion. 6) Diaphragmatic hernia: Transudate or modified transudate with herniated abdominal organs on radiographs. 7) Hypoproteinemia: Transudate due to decreased oncotic pressure, with low total protein on serum biochemistry. 8) Pericardial disease: Effusion with signs of right-sided heart failure and pericardial effusion on echocardiography. 9) Idiopathic pleural effusion: Diagnosis of exclusion, with no identifiable underlying cause. 10) Chylothorax: Confirmed by fluid analysis showing high triglyceride content and characteristic chylomicrons.

The diagnostic algorithm for chylothorax begins with a thorough history and physical examination, with emphasis on respiratory rate and effort, thoracic auscultation, and cardiac assessment. If pleural effusion is suspected, thoracic radiographs (lateral and dorsoventral views) are obtained to confirm the presence of fluid and assess the underlying lung fields and cardiac silhouette. Thoracocentesis is performed for fluid analysis, which is essential for diagnosis. The fluid is evaluated for appearance (milky, turbid), cell count, cytology, and biochemical parameters, including triglyceride and cholesterol concentrations. A triglyceride level greater than 100 mg/dL and a cholesterol-to-triglyceride ratio less than 1 confirm chylothorax. If the fluid is not overtly milky, a lipemia test or chylomicron electrophoresis may be performed. Once chylothorax is confirmed, further diagnostics are aimed at identifying the underlying cause. This includes echocardiography to assess cardiac function and rule out pericardial disease, abdominal ultrasound to evaluate for neoplasia or other abnormalities, and thoracic CT or MRI to identify masses, lymphadenopathy, or thoracic duct abnormalities. Lymphangiography, either via mesenteric lymph node injection or percutaneous popliteal lymph node injection, can be used to visualize the thoracic duct and identify the site of leakage. In cases of suspected trauma, a thorough search for other injuries is warranted. If no underlying cause is found, a diagnosis of idiopathic chylothorax is made.

Laboratory findings in chylothorax are primarily based on pleural fluid analysis. The fluid is typically a modified transudate or exudate with a milky, turbid appearance. The total nucleated cell count is usually low to moderate (1,000-10,000 cells/µL), with a predominance of small lymphocytes. The total protein concentration is variable, often between 2.5 and 5.0 g/dL. The triglyceride concentration is markedly elevated, typically greater than 100 mg/dL, and the cholesterol concentration is lower, with a cholesterol-to-triglyceride ratio less than 1. In chronic cases, the fluid may become more cellular and contain neutrophils and macrophages due to inflammation. Hematology and serum biochemistry are often unremarkable, but may reveal lymphopenia due to loss of lymphocytes in the chyle. In cases of underlying cardiac disease, elevated cardiac biomarkers such as NT-proBNP may be present. Coagulation parameters are typically normal, but should be assessed if surgery is planned. Inflammatory biomarkers such as C-reactive protein (CRP) may be elevated in cases with secondary inflammation.

Imaging plays a crucial role in the diagnosis and management of chylothorax. Thoracic radiographs are the initial imaging modality and typically show a pleural effusion pattern, with retraction of the lung lobes from the chest wall, blunting of the costophrenic angles, and a scalloped appearance of the lung margins. In chronic cases, evidence of fibrosing pleuritis may be seen as a thickened pleura or lung lobe atelectasis. Echocardiography is essential to evaluate cardiac structure and function, particularly to rule out right-sided heart failure, pericardial disease, or cardiomyopathy. Abdominal ultrasound may reveal underlying neoplasia or other abnormalities. Computed tomography (CT) with contrast is highly valuable for identifying thoracic masses, lymphadenopathy, and thoracic duct abnormalities. CT lymphangiography, performed by injecting contrast into a mesenteric lymph node or the popliteal lymph node, can delineate the thoracic duct and identify the site of leakage. Magnetic resonance imaging (MRI) may be used for soft tissue detail, but is less commonly employed. In cases of suspected trauma, thoracic CT can also identify rib fractures, pulmonary contusions, or other injuries.

Cytological examination of chylous fluid typically reveals a predominance of small lymphocytes, with occasional neutrophils and macrophages. The background may contain eosinophilic debris and fat droplets. The presence of chylomicrons can be confirmed with Sudan III staining. Histopathological examination of tissues is indicated when an underlying neoplastic or inflammatory cause is suspected. Biopsy of thoracic masses, lymph nodes, or the thoracic duct itself may be performed during surgery or via thoracoscopy. Histopathology can reveal lymphoma, thymoma, or other neoplasms, as well as granulomatous inflammation due to fungal infection. In cases of fibrosing pleuritis, histopathology of the pleura shows fibrous tissue proliferation and chronic inflammation. Special stains, such as immunohistochemistry for CD3 and CD20, may be used to differentiate T-cell and B-cell lymphomas.

The treatment of chylothorax involves both medical and surgical approaches. Initial management focuses on stabilizing the patient and addressing any underlying cause. Medical therapy includes therapeutic thoracocentesis to relieve respiratory distress, a low-fat diet supplemented with medium-chain triglycerides (MCTs) to reduce chyle production, and the administration of rutin, a benzopyrone that has been shown to reduce chyle production and promote lymphatic drainage. The recommended dose of rutin is 50 mg/kg orally every 8 hours in dogs and 50 mg/kg orally every 12 hours in cats. If an underlying cause is identified, such as heart failure or neoplasia, specific treatment is instituted. Surgical intervention is indicated if medical therapy fails after 2-4 weeks, or if the patient has recurrent effusions or fibrosing pleuritis. The most common surgical procedure is thoracic duct ligation, which involves ligating the thoracic duct at the level of the diaphragm to prevent chyle leakage. This is often combined with cisterna chyli ablation, which involves removing the cisterna chyli, a lymphatic sac in the abdomen, to reduce lymphatic flow. Other surgical options include pleuroperitoneal shunting, which diverts chyle from the pleural space to the peritoneal cavity, and pleurodesis, which involves the instillation of a sclerosing agent to obliterate the pleural space. In cases of fibrosing pleuritis, decortication, or surgical removal of the fibrous peel, may be necessary to allow lung expansion. The surgical approach for thoracic duct ligation is typically via a caudal thoracic approach, with the patient in lateral recumbency. The thoracic duct is identified and ligated with non-absorbable suture, such as 3-0 or 4-0 silk or polypropylene. Cisterna chyli ablation is performed via a cranial abdominal approach, with the cisterna chyli identified and removed. Postoperative management includes continued thoracocentesis as needed, pain management, and nutritional support.

The prognosis for chylothorax is variable and depends on the underlying cause and the presence of complications. In cases of traumatic chylothorax, the prognosis is generally good, with many patients responding to conservative management or surgical ligation. In idiopathic cases, the prognosis is guarded, with a reported success rate of 50-80% for thoracic duct ligation. The presence of fibrosing pleuritis significantly worsens the prognosis, as it impairs lung expansion and may require decortication. The overall mortality rate is approximately 20-30%, with the highest risk in chronic cases. Negative prognostic indicators include the presence of fibrosing pleuritis, underlying neoplasia, and failure to respond to medical therapy. Positive prognostic indicators include early diagnosis, absence of underlying disease, and successful surgical intervention.

Postoperative follow-up for chylothorax is essential to monitor for recurrence and complications. Patients should be re-evaluated at 1, 2, 4, and 8 weeks after surgery. Thoracic radiographs should be obtained at each visit to assess for pleural effusion and lung expansion. Thoracocentesis may be performed if effusion is present. The patient's respiratory rate and effort should be monitored, and any signs of respiratory distress should be addressed immediately. Dietary management with a low-fat diet and MCTs should be continued for at least 4-6 weeks postoperatively. Rutin therapy may be continued for 2-3 months. Activity should be restricted for 4-6 weeks to allow healing. Long-term follow-up is recommended every 3-6 months for the first year, with thoracic radiographs and clinical assessment. In cases of fibrosing pleuritis, long-term monitoring for respiratory function is necessary.

Clinical pearls: 1) Always confirm the diagnosis of chylothorax with fluid analysis, as not all milky effusions are chylous. 2) In cats, always evaluate for underlying cardiac disease, as hypertrophic cardiomyopathy is a common cause. 3) Thoracic duct ligation is most effective when performed early, before the development of fibrosing pleuritis. 4) Cisterna chyli ablation can improve the success rate of thoracic duct ligation. 5) Use a low-fat diet and rutin as adjunctive therapy to reduce chyle production. Pitfalls: 1) Failure to identify and treat the underlying cause can lead to recurrence. 2) Delaying surgery in cases that do not respond to medical therapy can result in fibrosing pleuritis, which is difficult to manage. 3) Incomplete ligation of the thoracic duct can lead to continued chyle leakage. 4) Postoperative chylothorax may occur due to collateral lymphatic vessels, so careful dissection and ligation of all visible branches is essential. 5) Avoid overzealous thoracocentesis, which can cause hypoproteinemia and electrolyte imbalances.

Perioperative drug protocols for chylothorax are based on Plumb's Veterinary Drug Handbook. Prophylactic antimicrobials: Cefazolin (22 mg/kg IV) administered 30 minutes before surgical incision and repeated every 90 minutes during surgery. Postoperative analgesics: Opioids such as hydromorphone (0.05-0.1 mg/kg IV or IM every 4-6 hours) or fentanyl CRI (2-5 µg/kg/h IV) for the first 24 hours. NSAIDs such as carprofen (2.2 mg/kg PO every 12 hours) or meloxicam (0.1 mg/kg PO every 24 hours) may be used after the first 24 hours if renal function is normal. Local anesthetic blocks: Intercostal nerve blocks with bupivacaine (1-2 mg/kg) or lidocaine (2 mg/kg) can provide additional analgesia. Muscle relaxants: Not routinely used, but may be considered in cases of severe respiratory distress. Chondroprotectants: Not applicable. Rutin: 50 mg/kg PO every 8 hours in dogs and every 12 hours in cats. Octreotide: A somatostatin analog that reduces lymphatic flow, may be used at 2-10 µg/kg SC every 8 hours. Furosemide: If heart failure is present, 1-2 mg/kg IV or PO every 8-12 hours. Nutritional support: Low-fat diet with MCTs, and if necessary, enteral feeding via esophagostomy tube.

Evidence-based literature on chylothorax in small animals includes several key studies. Fossum et al. (1991) reported a success rate of 50% for thoracic duct ligation in dogs with idiopathic chylothorax, with a higher success rate when combined with cisterna chyli ablation. Fossum et al. (2004) evaluated the use of rutin in dogs and cats with chylothorax, showing a response rate of 20-30% with medical management alone. A study by Radlinsky et al. (2002) compared thoracic duct ligation with and without cisterna chyli ablation, finding a higher success rate with the combined procedure. Another study by MacDonald et al. (2008) evaluated the use of octreotide in cats with chylothorax, showing a reduction in pleural effusion in some cases. A retrospective study by Singh et al. (2012) reported a success rate of 80% for thoracic duct ligation in dogs when performed early. The ACVS consensus statement on chylothorax recommends early surgical intervention in cases that do not respond to medical therapy within 2-4 weeks. Overall, the evidence supports surgical management as the most effective treatment for chylothorax, with the best outcomes when surgery is performed before the development of fibrosing pleuritis.